BIRMINGHAM, Ala. & CLEMMONS, N.C.–(BUSINESS WIRE)–Advancing Sight Network and Miracles In Sight today jointly announced the merger of the two organizations, which will begin operating as one on January 1, 2026. Globally, at least 253 million people l…
Category: Business
DefEYE, Inc. Announces Investment from ExSight Ventures
NEW YORK–(BUSINESS WIRE)–ExSight Ventures, a leading venture capital firm focused on transformational eye care innovations, today announced its investment in DefEYE, Inc., a rapidly growing ocular company developing decellularized placental-based tis…
PRISM Vision Group Marks Milestone in National Expansion with Spokane Eye Clinic Affiliation
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–PRISM Vision Group closed a transaction with Spokane Eye Clinic, through which Spokane Eye Clinic joins PRISM’s network of affiliated practices.
Tenpoint Therapeutics Ltd. Announces Submission of a New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia to the MFDS in South Korea
LONDON & SEATTLE & HONG KONG–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that its partner, Zhaoke…
LambdaVision Raises $7M Seed Round to Revolutionize Blindness Treatment Using Space-Based Manufacturing
WOODBRIDGE, Conn.–(BUSINESS WIRE)–LambdaVision, a biotech innovator leveraging microgravity to manufacture its investigational protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, has closed a $7M seed …
PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
FORT WORTH, Texas & MELBOURNE, Australia & MENLO PARK, Calif.–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, I…
Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific
SINGAPORE–(BUSINESS WIRE)–Eyexora Establishes Co-Headquarters in Singapore to Accelerate Growth Across Asia-Pacific
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent busine…
National Vision Holdings, Inc. Reports Third Quarter 2025 Financial Results
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision,” “we,” “our,” “us” or the “Company”) today reported its financial results for the third quarter ended September 27, 2025. “Our strong performance this quarter…
Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc. (“Alcon”) (NYSE: ALC) regarding its proposed acquisition of STAAR Surgical Company (“STAAR” o…
Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successf…
Glaukos Announces Participation in Upcoming Investor Conferences
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
HTC and IngenioSpec Settled ITC Dispute on Electronic Eyewear Products
WACO, Texas–(BUSINESS WIRE)– #audio–IngenioSpec Resolves Patent Dispute with HTC on Electronic Eyewear Technology.
Advancing Sight Network Receives $25,000 Grant from EyeSight Foundation of Alabama to Pursue Cures for Vision Loss
BIRMINGHAM, Ala.–(BUSINESS WIRE)–Advancing Sight Network, an Alabama-based nonprofit dedicated to preserving and restoring eyesight, has received a $25,000 grant from the EyeSight Foundation of Alabama and the Community Foundation of Greater Birmingh…
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
INCHEON, Korea–(BUSINESS WIRE)– #BYOOVIZ–Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimi…
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced achievement of statis…
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today issued the following statement reg…
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
GENEVA & LAKE FOREST, Calif.–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL), today …